Tvardi Therapeutics, Inc.
TVRD
$3.75
-$0.16-4.09%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | ||
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | |
| Total Other Revenue | -- | -- | -- | -- | |
| Total Revenue | -- | -- | -- | -- | |
| Cost of Revenue | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | |
| SG&A Expenses | 165.04% | 371.23% | 70.98% | 222.43% | |
| Depreciation & Amortization | -- | -- | -- | -- | |
| Other Operating Expenses | -- | -- | -- | -- | |
| Total Operating Expenses | 4.62% | 23.51% | -2.11% | 131.60% | |
| Operating Income | -4.62% | -23.51% | 2.11% | -131.60% | |
| Income Before Tax | -0.25% | 159.74% | -127.96% | -192.05% | |
| Income Tax Expenses | -- | -- | -- | -- | |
| Earnings from Continuing Operations | -0.25% | 159.74% | -127.96% | -192.05% | |
| Earnings from Discontinued Operations | -- | -- | -- | -- | |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | |
| Minority Interest in Earnings | -- | -- | -- | -- | |
| Net Income | -0.25% | 159.74% | -127.96% | -192.05% | |
| EBIT | -4.62% | -23.51% | 2.11% | -131.60% | |
| EBITDA | -4.64% | -23.58% | 2.12% | -132.28% | |
| EPS Basic | 72.47% | 118.65% | -127.71% | -191.07% | |
| Normalized Basic EPS | 72.47% | 118.65% | -127.73% | -191.06% | |
| EPS Diluted | 72.45% | 62.94% | -127.71% | -191.07% | |
| Normalized Diluted EPS | 72.47% | 118.19% | -127.73% | -191.06% | |
| Average Basic Shares Outstanding | 264.19% | 220.28% | 0.11% | 0.33% | |
| Average Diluted Shares Outstanding | 264.19% | 228.38% | 0.11% | 0.33% | |
| Dividend Per Share | -- | -- | -- | -- | |
| Payout Ratio | -- | -- | -- | -- | |